From Relypsa Gets Another $50M for Drug to Fight Excess Potassium:

relypsa

relypsa—

Underwriters and Partners

Xconomy Insight

Xconomy Insight · Special Report
Biotech Startups: How to Succeed in a COVID-19 World
Industry experts explain what it takes to launch a new biotech company

Sponsored · Webinar
Nov. 12 – High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocytes
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX

Sponsored · Whitepaper
Decentralized Clinical Trials: The Call for a New Paradigm
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences

Xconomy on Demand

We offer a number of ways to subscribe for free!